Skip to content
Free U.S. Standard shipping · Free international Standard shipping over US$150. Free U.S. shipping · International free over US$150.
Take the assessment

Explore HealthspanX

Narrative review

The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications

Bin Yu, Xiaotong Jing, Lina Jia, Maoru Wang, Liying Liu, Songyuge Ping, Yu Wang, Min Yang

Frontiers in Pharmacology · 2024 · 15:1436597

Original publication PubMed Full text on PMC

Study at a glance

Design
Broad literature review covering database records from inception through 20 May 2024; no formal meta-analysis.
Population or model
No direct participants; heterogeneous preclinical studies and human trials were reviewed.
Sample size
No direct sample; multiple animal studies and small human trials summarized
Intervention
Heterogeneous NMN exposures across laboratory models and human trials, including different doses, routes, formulations, and durations.
Publication type
Narrative review
Evidence class
review-perspective
Research area
NMN pharmacology, clinical evidence and applications
Trial registration
Not reported (review article)

Study endpoints

  • NMN chemistry, metabolism, and pharmacology
  • Preclinical effects across organ systems and disease models
  • Human safety, tolerability, NAD-related biomarkers, and selected functional outcomes
  • Dosing, product-quality, regulatory, and application considerations

Plain-language summary

This wide-ranging review covers how NMN is made and metabolized, proposed biological mechanisms, animal studies, human trials, and possible applications. Animal and laboratory studies report many effects, but human findings are less consistent and generally come from small, short trials. The review highlights unresolved questions about dose, long-term safety, product purity, individual variation, and regulation.

Key findings

The paper describes NMN as an NAD+ precursor with extensive mechanistic and preclinical research across metabolic, neurologic, cardiovascular, ocular, renal, reproductive, and other models. Human trials using roughly 100–1,250 mg/day for several weeks generally reported short-term tolerability and some biomarker or functional changes, but effects were less pronounced and less consistent than in animals. The authors note that clinical evidence remains limited and that standardized dosing, product quality, and regulatory approaches are lacking.

Limitations

The review is broad and narrative, with no formal risk-of-bias assessment or meta-analysis. It combines cell, animal, and human evidence across highly varied conditions, doses, routes, formulations, and outcomes. Much of the positive evidence is preclinical. Human studies were generally small and short, with inconsistent findings. Long-term safety, optimal dosing, product purity, individual variation, and regulatory status remain uncertain.

Funding and transparency

Funding

The authors declared that no financial support was received for the research, authorship, or publication of the article.

Competing interests

The authors declared that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

HealthspanX observation

The review spans basic chemistry, animal models, human trials, industrial uses, and proposed applications; these evidence types should not be treated as interchangeable.

Interpretive weight

Limited

The paper provides a broad literature map, but it is not a formal meta-analysis and much of the positive evidence is preclinical while human trials remain small and inconsistent.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Your cart (0)

Your cart is empty.

Explore Ultra Pure NMN, read the label and choose your pack when you’re ready.

Explore Ultra Pure NMNExplore the journal
HealthspanX

What are you looking for?

Useful starting points